

Pt	rCBV				rCBF			
	Max Enhancing	Max rCBV	Non-enhancing T2 hyperintensity	Contralateral NAWM	Max Enhancing	Max rCBV	Non-enhancing T2 hyperintensity	Contralateral NAWM
1	-68.42	-72.42	-51.43	21.48	-54.83	-61.46	-35.23	-45.21
2	-32.39	-71.77	160.57	-21.31	-45.13	-69.13	-22.62	37.05
3	67.54	-13.19	82.49	25.82	29.37	-26.37	45.23	-15.69
4	-53.85	-12.63	25.62	-35.12	-43.12	-14.31	21.87	63.31
5	18.93	-56.17	135.82	15.14	11.42	-58.71	142.72	-10.19
6	-29.53	-6.29	15.54	1.19	-29.17	-14.73	45.75	-18.08
7	-45.13	-79.18	-40.52	-58.23	-33.74	-77.35	-29.11	53.53
8	-37.53	-41.62	78.37	-3.76	-45.48	-46.50	114.59	27.19
9	-33.79	-49.32	-59.43	145.22	-33.43	-43.36	-42.42	-21.71
10	-18.11	-32.83	7.74	-19.75	-10.35	-32.88	9.11	3.17
11	-31.33	3.42	35.49	11.29	-27.13	14.53	33.42	-22.88
12	115.73	-55.83	97.37	-3.20	56.53	-67.61	65.57	73.83
13	23.58	40.85	183.42	-82.35	17.53	41.29	157.43	-55.71
14	-36.42	-40.98	-15.68	194.64	-35.47	-46.89	-13.66	49.91
15	-25.13	35.42	31.93	-2.33	-28.51	45.21	16.53	1.43
16	-60.73	-37.63	-35.13	-6.76	-56.33	2.32	-23.12	-3.89
17	50.51	-23.35	158.62	6.36	35.21	-25.63	150.48	-9.21
18	-0.39	-30.41	256.32	48.57	-22.32	-38.72	-67.79	67.99
19	3.41	-3.43	25.13	-15.47	23.15	-10.37	24.35	-67.63
20	5.71	22.24	31.28	-15.51	4.12	26.49	20.45	0.81
21	-5.17	-35.27	-8.15	-15.21	1.53	-28.63	-5.69	-1.54
22	-31.72	-14.83	-85.63	2.16	-28.19	-7.91	-70.27	51.49
23	39.75	-40.63	219.24	-7.61	45.79	-41.09	210.81	5.81
24	-24.59	-66.38	-62.91	-25.21	-17.32	-65.13	-65.93	-3.71
25	-30.89	-8.09	144.92	27.92	-65.53	-50.09	60.69	34.09